YD Bio (YDES) CEO details direct and indirect share stakes

Rhea-AI Filing Summary

YD Bio Ltd CEO Dr. Ethan Shen filed an initial ownership report showing 11,224,153 Ordinary Shares held directly and 43,120,858 held indirectly. The indirect holdings are owned through YD Biopharma Holding Limited and E820N Assets Ltd., which are ultimately controlled by The E820N Trust where Dr. Shen is settlor, protector and sole beneficiary.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Shen Ethan PhD

(Last) (First) (Middle)

C/O YD BIO LIMITED

12F., NO. 3, XINGNAN ST., NANGANG DIST.

(Street)

TAIPEI CITY 115001

(City) (State) (Zip)

TAIWAN, PROVINCE OF CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
YD Bio Ltd [ YDES ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	11,224,153	D
Ordinary Shares	43,120,858	I	See Footnotes(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ethan Shen	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Dr. Ethan Shen’s Form 3 filing for YDES disclose?

The filing shows Dr. Ethan Shen’s initial beneficial ownership in YD Bio Ltd, with 11,224,153 Ordinary Shares held directly and 43,120,858 held indirectly through entities ultimately owned by The E820N Trust.

How many YD Bio (YDES) shares does the CEO hold directly and indirectly?

Dr. Shen reports 11,224,153 Ordinary Shares held directly and 43,120,858 held indirectly via YD Biopharma Holding Limited and E820N Assets Ltd., entities ultimately controlled by The E820N Trust benefiting him.

Are the indirect YDES holdings controlled by a trust for Dr. Shen?

Yes. The indirect Ordinary Shares are held by YD Biopharma Holding Limited, owned by E820N Assets Ltd., which is wholly owned by The E820N Trust, where Dr. Shen is settlor, protector and sole beneficiary.

Does this YDES Form 3 show any recent share purchases or sales?

No. The Form 3 reflects Dr. Shen’s existing beneficial ownership positions, listing direct and indirect holdings of Ordinary Shares, rather than reporting new purchases, sales, or other transactional activity in the company’s stock.

What is the significance of The E820N Trust in YD Bio (YDES) ownership?

The E820N Trust ultimately owns the entities holding Dr. Shen’s indirect YD Bio shares. As settlor, protector and sole beneficiary, Dr. Shen is treated as the beneficial owner of those indirectly held Ordinary Shares under this structure.